Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Dechra Pharmaceuticals PLC
  6. Summary
    DPH   GB0009633180

DECHRA PHARMACEUTICALS PLC

(DPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
4868(c) 4902(c) 4914(c) 4970(c) 5035(c) Last
123 124 232 168 97 626 147 968 245 333 Volume
+0.58% +0.70% +0.24% +1.14% +1.31% Change
More quotes
Estimated financial data (e)
Sales 2021 605 M 840 M 840 M
Net income 2021 60,7 M 84,2 M 84,2 M
Net Debt 2021 168 M 233 M 233 M
P/E ratio 2021 91,6x
Yield 2021 0,77%
Sales 2022 648 M 900 M 900 M
Net income 2022 67,5 M 93,8 M 93,8 M
Net Debt 2022 95,3 M 132 M 132 M
P/E ratio 2022 84,5x
Yield 2022 0,82%
Capitalization 5 449 M 7 573 M 7 563 M
EV / Sales 2021 9,28x
EV / Sales 2022 8,55x
Nbr of Employees -
Free-Float 98,4%
More Financials
Company
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra... 
Sector
Pharmaceuticals
Calendar
09/06Earnings Release
More about the company
Ratings of Dechra Pharmaceuticals PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about DECHRA PHARMACEUTICALS PLC
07/13DECHRA PHARMACEUTICALS : JPMorgan Lifts Dechra's PT, Affirms Overweight Rating
MT
07/12London Shares Fall as Miners, Banks Lose Ground
DJ
07/12FTSE 100 Falls, Pound Faces Hit From Another Potential Lockdown
DJ
07/12DECHRA PHARMACEUTICALS' : Fiscal 2021 Revenue Jumps 18%
MT
07/12Dechra Pharmaceuticals PLC Announces Preliminary Revenue Results for the Year..
CI
06/08DECHRA PHARMACEUTICALS : Bumps Up FY21 Revenue Outlook
MT
04/13DECHRA PHARMACEUTICALS : To Commercialize Intervacc's Strangvac in Europe
MT
04/12INTERVACC AB : and Dechra Pharmaceuticals PLC enter into an Agreement to Commerc..
AQ
04/12Intervacc AB and Dechra Pharmaceuticals plc Enter into an Agreement to Commer..
CI
03/31Dechra Pharmaceuticals PLC Announces Directorate Changes
CI
03/04DECHRA PHARMACEUTICALS PLC : Ex-dividend day for interim dividend
FA
03/02DECHRA PHARMACEUTICALS : Jefferies Downgrades Dechra Pharmaceuticals to Hold fro..
MT
02/24DECHRA PHARMACEUTICALS : Half Yearly Presentation for the Period ended 31 Decemb..
PU
02/23DECHRA PHARMACEUTICALS : JPMorgan Raises Dechra Price Target, Keeps Overweight R..
MT
02/22Dechra Pharmaceuticals to Seek Acquisitions
CI
More news
News in other languages on DECHRA PHARMACEUTICALS PLC
07/12MADRID STOCK EXCHANGE : Atención, ísemana ocupada!
07/12STOCK MARKET PARIS : Attention, semaine chargée !
07/12EN DIRECT DES MARCHES : Atos, AXA, McPhy, Poxel, Keyrus, Virgin Galactic, Volksw..
03/02Cycliques, Technologiques, tout grimpe
03/02AVIS D'ANALYSTES DU JOUR : L'Oréal, Logitech, Technip Energies, Vestas, Virbac, ..
More news
Analyst Recommendations on DECHRA PHARMACEUTICALS PLC
More recommendations
Chart DECHRA PHARMACEUTICALS PLC
Duration : Period :
Dechra Pharmaceuticals PLC Technical Analysis Chart | DPH | GB0009633180 | MarketScreener
Technical analysis trends DECHRA PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 50,35 GBX
Average target price 4 630,00 GBX
Spread / Average Target 9 096%
EPS Revisions
Managers and Directors
Ian David Page Chief Executive Officer & Executive Director
Paul Sandland Chief Financial Officer & Executive Director
William Anthony Rice Non-Executive Chairman
Susan Longhofer Chief Scientific Officer
Allen Mellor Director-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
DECHRA PHARMACEUTICALS PLC44.06%7 479
ZOETIS INC.22.48%96 235
ELANCO ANIMAL HEALTH INCORPORATED18.91%17 250
VIRBAC43.07%3 408
JINYU BIO-TECHNOLOGY CO., LTD.-15.46%3 071
WUHAN KEQIAN BIOLOGY CO.,LTD-30.19%2 045